Ikarian Capital, LLC Exits Position in Karyopharm Therapeutics Inc.

This Schedule 13G filing, dated May 15, 2026, indicates that Ikarian Capital, LLC and Neil Shahrestani have fully exited their position in Karyopharm Therapeutics Inc. (KPTI). As of the event date of March 31, 2026, the reporting persons report owning zero shares of common stock, representing 0.0% of the class. Ikarian Capital, a registered investment adviser, previously held these shares through a fund and various separately managed accounts. Neil Shahrestani, who indirectly controls Ikarian Capital, is also named as a reporting person. The filing serves as a formal notice that the group has ceased to be beneficial owners of more than five percent of the issuer's common stock. The securities were originally held in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. The principal business office for the reporting persons is located in Dallas, Texas.